Maven Securities LTD purchased a new stake in Organon & Co. (NYSE:OGN – Free Report) in the 2nd quarter, according to its most recent filing with the SEC. The fund purchased 434,200 shares of the company’s stock, valued at approximately $5,879,000. Maven Securities LTD owned about 0.17% of Organon & Co. as of its most recent filing with the SEC.
Other large investors also recently made changes to their positions in the company. Allied Private Wealth LLC acquired a new stake in shares of Organon & Co. during the second quarter worth $33,000. Nykredit A S purchased a new position in Organon & Co. during the second quarter worth about $76,000. GAMMA Investing LLC lifted its position in Organon & Co. by 69.8% during the second quarter. GAMMA Investing LLC now owns 5,782 shares of the company’s stock worth $78,000 after buying an additional 2,376 shares during the period. Eurizon Capital SGR S.p.A. purchased a new position in Organon & Co. during the fourth quarter worth about $44,000. Finally, Kestra Advisory Services LLC acquired a new stake in Organon & Co. in the 4th quarter worth about $47,000. Hedge funds and other institutional investors own 77.43% of the company’s stock.
Analyst Upgrades and Downgrades
Separately, Weiss Ratings cut Organon & Co. from a “hold (c)” rating to a “hold (c-)” rating in a report on Monday, August 3rd. Five research analysts have rated the stock with a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, Organon & Co. currently has a consensus rating of “Reduce” and a consensus target price of $11.40.
Organon & Co. Stock Performance
NYSE:OGN opened at $13.77 on Wednesday. The company has a market cap of $3.61 billion, a P/E ratio of 17.88, a P/E/G ratio of 1.28 and a beta of 1.52. The firm’s 50 day moving average is $13.62 and its two-hundred day moving average is $11.43. Organon & Co. has a fifty-two week low of $5.69 and a fifty-two week high of $13.78. The company has a quick ratio of 1.44, a current ratio of 1.95 and a debt-to-equity ratio of 8.43.
Organon & Co. Announces Dividend
The company also recently disclosed a quarterly dividend, which will be paid on Thursday, September 10th. Stockholders of record on Friday, August 14th will be issued a dividend of $0.02 per share. This represents a $0.08 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date is Friday, August 14th. Organon & Co.’s dividend payout ratio is presently 10.39%.
Organon & Co. Profile
Organon & Co is a global healthcare company that was established as an independent, publicly traded entity following its spin-off from Merck & Co in June 2021. Headquartered in Jersey City, New Jersey, Organon focuses on delivering therapeutic solutions across women’s health, biosimilars, and established brands. The company’s creation reflected a strategic effort to concentrate on specialty pharmaceuticals and legacy products with proven patient impact.
In women’s health, Organon provides a broad portfolio of products addressing reproductive and gynecological conditions, including fertility treatments, contraception, and hormone replacement therapies.
Featured Stories
- Five stocks we like better than Organon & Co.
- Tesla’s Robotaxi Launch Wasn’t the Moment Investors Expected
- Despite Post-Earnings Drop, Wall Street Analysts Eye New Highs for Broadcom Stock
- Morgan Stanley Eyes Good Things Ahead for Meta After $18 Billion Legal Settlement
- Q3 Earnings Could Be the Catalyst the Market Has Been Waiting For
Receive News & Ratings for Organon & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organon & Co. and related companies with MarketBeat.com's FREE daily email newsletter.
